- Home
- SLN vs OSBC Comparison
SLN vs OSBC Comparison
Compare SLN & OSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLN | OSBC |
|---|---|---|
| Founded | 1994 | 1981 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SLN | OSBC |
|---|---|---|
| Price | $19.78 | $25.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $19.75 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 4.3M | 581.7K |
| Earning Date | 11-24-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 1.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.58 |
| Revenue | ★ $559,000.00 | N/A |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | $131.31 | $1.47 |
| P/E Ratio | ★ N/A | $15.86 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.19 | $17.61 |
| 52 Week High | $19.87 | $26.06 |
Technical Indicators
Market Signals| Indicator | SLN | OSBC |
|---|---|---|
| Relative Strength Index (RSI) | 78.28 | 54.40 |
| Support Level | $13.01 | $24.18 |
| Resistance Level | $19.87 | $25.77 |
| Average True Range (ATR) | 0.07 | 0.71 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 60.42 | 63.07 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.